Peptide science at the intersection of diet, metabolism, and performance.

Peptidegenics

An independent reference on how peptides interact with diet, metabolism, body composition, and training. No supplements sold. No affiliates. No agenda.

Browse by Metabolic Context

All contexts →
Caloric Deficit & Fat Loss

How peptides affect fat oxidation, muscle retention, and metabolic rate during energy restriction.
Anabolic Environment & Muscle

Growth hormone axis peptides, mTOR, protein synthesis, and what training stimulus has to do with it.
Fasting & Metabolic Switching

Peptide interactions with fasting windows, ketosis, autophagy, and insulin signalling.
Performance & Recovery Nutrition

Pre- and post-training peptide timing, recovery nutrition context, and substrate utilisation.

Latest Articles

View all →
Metabolic Performance Extrapolated

Does Retatrutide's Triple-Receptor Mechanism Produce Greater Fat-Mass Reduction Than Semaglutide or Tirzepatide Under Equal Calorie and Exercise Conditions in 2026?

Retatrutide is a triple incretin agonist that produced 24.2 percent mean body-weight loss at 48 weeks in Phase 2, numerically exceeding both semaglutide and tirzepatide. No controlled trial has matched calorie intake and exercise exposure across all three agents. The fat-mass-specific advantage therefore remains mechanistically inferred rather than directly demonstrated in a head-to-head design.

August 5, 2026 · 9 min read
Metabolic Performance Extrapolated

Does the 2026 Phase 4 Tirzepatide Trial in HIV Expect Epigenetic Aging Deceleration to Track With Visceral Fat Loss?

A 2026 Phase 4 trial actively recruiting virally suppressed adults with HIV tests whether tirzepatide's dual GIP/GLP-1 co-agonism can simultaneously reduce epigenetic aging pace and restore metabolic markers — and whether those changes correlate with visceral fat and lean mass shifts. HIV-associated visceral adiposity and chronic immune activation are independent epigenetic clock accelerants; tirzepatide targets both axes simultaneously.

August 5, 2026 · 9 min read
Metabolic Performance Extrapolated

Does Resistance Training Fundamentally Change How GLP-1 Therapies Like Semaglutide Affect Lean Mass in 2026?

Yes — resistance training fundamentally alters lean-mass outcomes during GLP-1 therapy. Without it, semaglutide users lose 25–40% of total weight as lean tissue. Controlled exercise interventions reduce that fraction to roughly 10–15% by activating a RAGULATOR-independent mTORC1 pathway that operates even under deep caloric deficits, while protein intake above 1.6 g/kg/day adds a mechanistically distinct, additive protective signal.

August 4, 2026 · 9 min read
Metabolic Oncology Extrapolated

How Do Semaglutide's 2026 Oncogenic and Cardiotoxicity Numbers Recalibrate the Risk-Benefit Equation for Body-Composition Practitioners?

A 2026 narrative review in Pharmaceuticals (MDPI) and ASCO 2026 real-world data reframe semaglutide's oncogenic and cardiotoxicity profile in quantitative terms. Key figures include a 21% preferential visceral fat reduction, a weight-independent 20% MACE reduction, and 38 to 50% lower metastatic progression rates across four obesity-linked cancers. These numbers shift the risk-benefit calculus decisively toward net benefit for body-composition practitioners.

July 29, 2026 · 9 min read
Clinical Review Extrapolated

What Does the 2026 Springer Review Reveal About Tirzepatide's Cardio-Renal Integration Mechanisms and Their Metabolic Performance Implications?

The 2026 Springer review in Endocrine (doi:10.1007/s12020-026-04686-5) identifies tirzepatide's cardio-renal axis as a mechanistically distinct integration layer. Dual GIP/GLP-1 receptor co-agonism reduces left ventricular mass, lowers NT-proBNP, cuts composite cardiorenal events versus dulaglutide, and slows eGFR decline — outcomes that reframe tirzepatide's value for metabolically compromised performance users carrying cardiovascular risk.

July 27, 2026 · 9 min read
Metabolic Longevity Extrapolated

What Structural Features of Dietary Geroprotective Peptides Enable Nrf2, IIS, and mTOR Modulation for Metabolic Longevity in 2026?

Dietary geroprotective peptides modulate Nrf2, IIS, and mTOR through three converging structural rules: molecular weight below 1 kDa for intestinal permeation, hydrophobic or aromatic C-terminal residues for Keap1 displacement and receptor docking, and ETGE-like sequence motifs that mimic endogenous signaling ligands. These features are now mappable by AI-driven structure-activity pipelines, directly linking food-protein sequence to conserved longevity network outputs.

July 23, 2026 · 10 min read
75%
mean increase in IGF-1 levels with CJC-1295 at 12 weeks
— Teichman et al., 2006, JCEM

Browse by Category

All Articles Clinical Review Metabolic Metabolic Longevity Metabolic Oncology Metabolic Performance Metabolic Signalling Preclinical Regulatory

About Peptidegenics

Learn more →

Peptidegenics covers the intersection of peptide biochemistry, nutrition science, and metabolic physiology. Every article is grounded in published research. Nothing is sold here.

The Metabolic Applicability Rating on each article answers the question the performance-focused reader actually asks: does this evidence apply to how I actually eat and train, or is this a lab finding I cannot act on?

About this publication  ·  Editorial policy & the Metabolic Applicability Rating →